Salt Lake City, Utah. Carterra® Inc., the world leader in high-throughput antibody screening and characterization, has announced that Joseph D. Keegan, PhD has been appointed as Executive Chairman of the Board of Directors.
Dr. Keegan has been a member of Carterra’s board for the last five years and has over 30 years of experience leading public and private life science platform companies. As CEO of ForteBio, Inc., he established product development and commercial strategies that resulted in its rapid growth and acquisition by Pall Corporation. During his nine-year tenure as CEO of Molecular Devices Corporation (MDC), he grew the company’s revenues through internal growth and acquisitions. In early 2007, he oversaw the acquisition of MDC by MDS Corporation for $615M.
“We are pleased to welcome Dr. Joe Keegan as Executive Chairman at this exciting time in the growth of the company,” said Josh Eckman, Carterra’s Chief Executive Officer. “Our flagship platform, the Carterra LSA, is disrupting the traditional antibody discovery workflow and playing a key role in speeding the development of biotherapeutics for a variety of diseases, including COVID-19. Dr. Keegan’s leadership experience in analytical instrumentation will be significant to our continued growth and success.”
Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University. He currently serves on a number of Boards of Directors, including those of Bio-Techne (NASDAQ:TECH) and Interpace Biosciences (NASDAQ:IDXG). Dr. Keegan’s proven experience with building innovative life science companies will help guide Carterra as it expands its unique protein and antibody characterization platform globally with additional products, assays, and analytical capabilities.
“I am excited about assuming the role of Executive Chairman at Carterra,” stated Dr. Keegan. “I look forward to working alongside my fellow board members and company leadership to bring the world’s highest throughput, lowest sample consumption and most multiplexed label-free biosensor platform to every corner of the globe.”
About Carterra, Inc.
Carterra® is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA™ instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, and Munich, Germany. For additional information, please visit www.carterra-bio.com.